BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scotto R, Buonomo AR, Moriello NS, Maraolo AE, Zappulo E, Pinchera B, Gentile I, Borgia G. Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. RRCT 2019;14:173-82. [DOI: 10.2174/1574887114666190306154650] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
2 Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol. 2019;13:839-848. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
3 Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, Marra F, Puoti M, Wedemeyer H. EASL recommendations on treatment of hepatitis C: Final update of the series☆. Journal of Hepatology 2020;73:1170-218. [DOI: 10.1016/j.jhep.2020.08.018] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 56.5] [Reference Citation Analysis]
4 Sims OT, Truong DN, Wang K, Melton PA, Atim K. Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center. J Racial Ethn Health Disparities 2021. [PMID: 34254269 DOI: 10.1007/s40615-021-01105-5] [Reference Citation Analysis]
5 Maraolo AE, Scotto R, Zappulo E, Pinchera B, Schiano Moriello N, Nappa S, Buonomo AR, Gentile I. Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Rev Anti Infect Ther 2020;18:191-202. [PMID: 32011191 DOI: 10.1080/14787210.2020.1725473] [Reference Citation Analysis]
6 Macgregor L, Ward Z, Martin NK, Nicholls J, Desai M, Hickson F, Weatherburn P, Hickman M, Vickerman P. The cost-effectiveness of case-finding strategies for achieving hepatitis C elimination among men who have sex with men in the UK. J Viral Hepat 2021;28:897-908. [PMID: 33759257 DOI: 10.1111/jvh.13503] [Reference Citation Analysis]
7 Suciu A, Abenavoli L, Pellicano R, Luzza F, Dumitrascu DL. Transaminases: oldies but goldies. A narrative review. Minerva Gastroenterol Dietol 2020;66:246-51. [PMID: 31994373 DOI: 10.23736/S1121-421X.20.02660-4] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Borgia G, Scotto R, Buonomo AR. An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. Expert Opin Investig Drugs 2019;28:395-7. [PMID: 30943797 DOI: 10.1080/13543784.2019.1602766] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Scotto R, Buonomo AR, De Pascalis S, Nerilli M, Pinchera B, Staiano L, Mercinelli S, Cattaneo L, Stanzione M, Stornaiuolo G, Martini S, Messina V, Coppola C, Coppola N, Gentile I. Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results. Expert Rev Gastroenterol Hepatol 2021;15:1057-63. [PMID: 33573411 DOI: 10.1080/17474124.2021.1890029] [Reference Citation Analysis]
10 Macgregor L, Desai M, Martin NK, Nicholls J, Hickson F, Weatherburn P, Hickman M, Vickerman P. Scaling up screening and treatment for elimination of hepatitis C among men who have sex with men in the era of HIV pre-exposure prophylaxis. EClinicalMedicine 2020;19:100217. [PMID: 32140664 DOI: 10.1016/j.eclinm.2019.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
11 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zarębska‐michaluk D, Jaroszewicz J, Pabjan P, Łapiński TW, Mazur W, Krygier R, Dybowska D, Halota W, Pawłowska M, Janczewska E, Buczyńska I, Simon K, Dobracka B, Citko J, Laurans Ł, Tudrujek‐zdunek M, Tomasiewicz K, Piekarska A, Sitko M, Białkowska‐warzecha J, Klapaczyński J, Sobala‐szczygieł B, Horban A, Berak H, Deroń Z, Lorenc B, Socha Ł, Tronina O, Flisiak R. Is an 8‐week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real‐world experience? Journal of Gastroenterology and Hepatology 2021;36:1944-52. [DOI: 10.1111/jgh.15337] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Uribe-Noguez LA, Mata-Marín JA, Ocaña-Mondragón A, Pompa-Mera EN, Ribas-Aparicio RM, Arroyo-Anduiza CI, Gomez-Torres ME, Chaparro-Sánchez A, Gaytán-Martínez J, Mauss S. Comparison of direct sequencing of the NS5B region with the Versant HCV genotype 2.0 assay for genotyping of viral isolates in Mexico. J Infect Chemother 2020;26:205-10. [PMID: 31537472 DOI: 10.1016/j.jiac.2019.08.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Buonomo AR, Scotto R, Coppola C, Pinchera B, Viceconte G, Rapillo CM, Staiano L, Saturnino M, Scarano F, Portunato F, Pisaturo M, De Pascalis S, Martini S, Tosone G, Nappa S, Coppola N, Gentile I. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort). Medicine (Baltimore) 2020;99:e18948. [PMID: 32028404 DOI: 10.1097/MD.0000000000018948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]